RESUMO
Background: obesity may establish a crucial barrier for effective fertility treatment in polycystic ovary syndrome [PCOS] females
Objective: to compare results of intra-cytoplasmic sperm injection [ICSI] in females with and without polycystic ovarian syndrome and further appraise the effect of obesity in PCOS females
Materials and Methods: a cross-sectional study from June 2015 to July 2016 included non-PCOS and PCOS [recognized by Rotterdam criteria] females who underwent ICSI. The PCOS were further stratified into non-obese and Obese according to the South Asian criteria for body mass index. Results were categorized on the basis of beta-human chorionic gonadotropin [beta-hCG] and transvaginal scan into non-pregnant [beta-hCG <25 mIU/ml], preclinical abortion [beta-hCG >25 mIU/ml with no fetal cardiac activity] and clinical pregnancy [beta-hCG >25 mIU/ml with fetal cardiac activity on transvaginal scan]. In addition, reproductive outcomes; implantation rate, clinical pregnancy rate and miscarriage rate among obese and non-obese PCOS and non-PCOS patients were compared
Results: our results revealed 38.5% clinical pregnancy rate in non-PCOs females, 23.8% in non-obese PCOS females whereas 26.4% in obese PCOS. Preclinical abortions were found to be highest [31.5%] in non-obese PCOS females and were the lowest [26.2%] in non-PCOS females. In non-PCOS group and non-obese PCOS females 35.4% and 44.6%, respectively, failed to become pregnant
Conclusion: the success after ICSI in terms of number of clinical pregnancies was more in non-PCOS patients as compared to PCOS. Increase in body mass index reflected a negative impact on the reproductive outcome in PCOS patients
RESUMO
The present study was designed to investigate the role of the 5-HT [7] receptors in lordosis and release of LH and compare the lordotic responses with 5-HT [IA] agent. Ovariectomised but oestradiol benzoate [OB] [10 micro g] for 48 h plus by progesterone [0.5 mg]- primed receptive rats were used for the study. Thirty min. prior to progesterone 5-HT [IA] and 5-: HT [7] agonists were administered intra-peritoneally [i.p.]. Lordotic quotient and release of LH were measured. Agonistic effect was then antagonized by respective antagonists. Effects on the above parameters were noted and correlated for possible interplay. 5-HT [7] agonist mimicked inhibitory effect of 8-OH DPAT on lordosis in receptive rats, however, the response was generally attenuated. Treatment by 5-HT [IA] antagonist, WAY 100135 causing a protective effect was evident transiently. Attenuation of lordotic quotient was again evident in rats treated with 5-HT [7] antagonist. 5-HT and the 5-HT [IA/7] receptor agonist, 8-OH-DPAT, injected i.p. into the female rat inhibit the LH release and the effects of both are blocked by 5-HT [IA] antagonist, WAY 100135 and 5-HT [7] antagonist, SB 269970-A as both 5-HT [IA] agonist, 8-OH-DPAT and 5-HT [7] agonist, 5-CT have moderate activity at the 5-HT [7] receptor subtype, indicating the possibility that this subtype might mediate these effects has been investigated. Ovariectomised but steroids primed rats induces an LH surge. [5-CT], a potent but non-selective agonist at 5-HT [7] receptors, like 5-HT and 8-OH-DPAT inhibited the LH surge at 2 mg injected i.p. The selective 5-HT [7] receptor antagonist SB-269970-A blocked LH surge when given systemically at both 5-HT [IA] and 5-HT [7] receptor subtypes. These data indicate that 5-HT [7] receptors play a role in the regulation of lordosis and release of LH and there exist a direct correlation between the two